CompletedInterventional · Phase 2NCT04456998 ↗A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
TerminatedInterventional · Phase 2NCT04816604 ↗An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)Irina SobolPIInterventionDrug: GB002 (seralutinib) · Device: Generic Dry Powder InhalerDatesApr 2021 – Sep 2026SponsorGossamer BioPulmonary Arterial Hypertension